This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of ~~Compounds of the~~ formula I



I

in which

$Ar^1$, $Ar^2$, $Ar^3$ each, independently of one another, denote an aromatic radical or Het, each of which is unsubstituted or mono-, di- or polysubstituted by $R^1$,

Het denotes a mono- or bicyclic aromatic heterocycle having 1, 2, 3 or 4 N, O and/or S atoms,

$R^1$ in each case, independently, denotes H, A, aryl, $OR^4$, $SR^4$, Oaryl, Saryl, $N(R^4)_2$, NHaryl, Hal, $NO_2$, CN, $(CH_2)_mCOOR^4$, $(CH_2)_mCOOaryl$, $(CH_2)_mCON(R^4)_2$, $(CH_2)_mCONHaryl$, $COR^4$, COaryl, $S(O)_mA$, $S(O)_maryl$, NHCOA, NHCOaryl, $NHSO_2A$, $NHSO_2aryl$ or $SO_2N(R^4)_2$, $O(CH_2)_n N(R^4)_2$, $O(CH_2)_nNHR_3$, $O(CH_2)_nNH_2$, $O(CH_2)_n$-morpholine, $O(CH_2)_n$-piperazine, $O(CH_2)_n$-pyrrolidine, $O(CH_2)_n$-piperidine, O-piperidine, $O(CH_2)_n$-oxopiperazine, $O(CH_2)_n$-oxomorpholine, $O(CH_2)_n$-oxopyrrolidine, $O(CH_2)_nC(CH_3)_2$-$(CH_2)_nN(R^4)_2$, $N(CH_2)_nC(CH_3)_2(CH_2)_nN(R^4)_2$, $O(CH_2)_nN(R^4)SO_mA$, $O(CH_2)_nN(R^4)SO_mN(R^4)A$, $O(CH_2)_nN(R^4)SO_maryl$, $(CH_2)_nN(R^4)SO_mA$, $(CH_2)_nN(R^4)SO_mN(R^4)A$, $(CH_2)_nN(R^4)SO_maryl$, $O(CH_2)_nSO_mA$, $O(CH_2)_nSO_mN(R^4)A$, $O(CH_2)_nSO_maryl$, $(CH_2)_nSO_mA$, $(CH_2)_nSO_mN(R^4)A$ or ~~and/or~~ $(CH_2)_nSO_maryl$,

Y denotes O, S, C-$NO_2$, $C(CN)_2$ or N-$R^3$,

Z denotes $G^1{}_n$, $G^1{}_nEG^2{}_m$, $EG^1{}_nG^2{}_m$ or $G^1{}_nG^2{}_mE$,

$R^2$, $R^3$, $R^4$ each, independently of one another, denote H, A or -alkylene-aryl,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two $CH_2$ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by Hal,

aryl denotes phenyl which is unsubstituted or mono-, di- or polysubstituted by A, phenyl,

OA, SA, Ophenyl, $NH_2$, $NA_2$, Hal, $NO_2$, CN, $(CH_2)_mCOOR^4$, $(CH_2)_mCON(R^4)_2$, $COR^4$, COaryl, $S(O)_mA$, NHCOA or NHSO2A,

E denotes O, $SO_m$, $NR^1$, CO, C=N or alkene,

$G^1$, $G^2$ each, independently of one another, denote $CR^1R^1$ or E,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2, 3, 4 or 5, and

m denotes 0, 1 or 2,

or a ~~and~~ pharmaceutically acceptable salt thereof ~~salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

2. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, in which

$Ar^1$ denotes phenyl which is mono- or disubstituted by $R^1$,

~~and the pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

3. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, in which

$Ar^2$ denotes unsubstituted phenyl,

~~and the pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

4. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, in which

$Ar^3$ denotes pyridinyl which is monosubstituted by $R^1$,

~~and the pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

5. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, in which

Y denotes O or S,

~~and the pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

6. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, in which

Z denotes O or $CR^1R^1$,

~~and the pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof,~~

~~including mixtures thereof in all ratios~~.

7. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, in which

$R^2$ denotes H,

~~and the pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

8. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, in which

$R^1$ in each case, independently, denotes H, A, Hal, OH, OA, $CF_3$ or ~~and/or~~ $CONHA_2$

~~and the pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

9. (Currently Amended) A compound ~~Compounds~~ according to Claim 1, in which

$Ar^1$ denotes phenyl which is mono- or disubstituted by $R^1$,

$Ar^2$ denotes unsubstituted phenyl,

$Ar^3$ denotes pyridinyl which is monosubstituted by $R^1$,

Y denotes O or S,

Z denotes O or $CR^1R^1$,

$R^2$ denotes H, and

$R^1$ in each case, independently, denotes H, A, Hal, OH, OA, $CF_3$ or ~~and/or~~ $CONHA_2$

~~and the pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios~~.

10. (Currently Amended) A compound ~~Compounds~~ according to Claim 1 selected from the group consisting of

a) N-methyl-4-[3-(2-hydroxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

b) N-methyl-4-[4-(2-hydroxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

c) N-methyl-4-[3-(2-hydroxy-5-methylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

d) N-methyl-4-[4-(2-hydroxy-5-methylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

e) N-methyl-4-[4-(2-hydroxy-4-methylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

f) N-methyl-4-[3-(4-fluoro-2-hydroxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

g) N-methyl-4-[3-(5-chloro-2-hydroxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

h) N-methyl-4-[3-(4-chloro-2-hydroxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

i) N-methyl-4-[3-(2,5-dimethoxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

j) N-methyl-4-[3-(5-chloro-2-methoxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

k) N-methyl-4-[3-(5-tert-butyl-2-hydroxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

l) N-methyl-4-[3-(hydroxytrifluoromethylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

m) N-methyl-4-[3-(2-methoxy-5-trifluoromethylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

n) N-methyl-4-[3-(5-ethanesulfonyl-2-hydroxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

o) N-methyl-4-{3-[2-(2-dimethylaminoethoxy)-5-trifluoromethylphenylcarbamoyl]-phenoxy}pyridine-2-carboxamide

p) N-methyl-4-[3-(2-methoxy-5-trifluoromethylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

q) N-methyl-4-[3-(3-trifluoromethanesulfonylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

r) N-methyl-4-[3-(1H-indazol-7-ylcarbamoyl)phenoxy]pyridine-2-carboxamide

s) N-methyl-4-[3-(1H-indol-7-ylcarbamoyl)phenoxy]pyridine-2-carboxamide

t) N-methyl-4-[3-(5-bromo-1H-indol-7-ylcarbamoyl)phenoxy]pyridine-2-carboxamide

u) N-methyl-4-[3-(5-tert-butyl-2-methoxyphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

v) N-methyl-4-[3-(3-trifluoromethylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

w) N-methyl-4-[3-(4-trifluoromethylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

x) N-methyl-4-[3-(2-methoxy-5-methylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide\

y) N-methyl-4-[3-(3-chloro-4-fluorophenylcarbamoyl)phenoxy]pyridine-2-carboxamide

z) N-methyl-4-[3-(3-chlorophenylcarbamoyl)phenoxy]pyridine-2-carboxamide

aa) N-methyl-4-[3-(4-fluoro-3-trifluoromethylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide and

bb) N-methyl-4-[3-(3-fluoro-4-trifluoromethylphenylcarbamoyl)phenoxy]pyridine-2-carboxamide

and ~~the~~ pharmaceutically acceptable salts~~, derivatives, solvates and stereoisomers thereof, including mixtures~~ thereof ~~in all ratios~~.

11. (Withdrawn and Currently Amended) A process for preparing a compound of claim 1, comprising reacting a compound of ~~Process for the preparation of compounds of the formula I and physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, characterised in that a compound of the~~ formula II



II

in which $Ar^1$ and $R^2$ have the meanings indicated for the compound of formula I ~~in Claim 1~~, ~~is reacted~~ with a compound of ~~the~~ formula III



III

in which Y, $Ar^2$, Z and $Ar^3$ have the meanings indicated for the compound of formula I ~~in Claim 1~~ and

L denotes Cl, Br, I or a free or reactively functionally modified OH group,

and/or a base or acid of the compound of formula I is converted into one of its salts.

12. (Withdrawn and Currently Amended) A pharmaceutical composition ~~Medicaments~~ comprising at least one compound according to Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier ~~and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants~~.

13. (Withdrawn and Currently Amended) A pharmaceutical composition according to claim 12, further comprising an additional pharmaceutically active ingredient ~~Medicaments comprising at least one compound according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient~~.

14. (Withdrawn and Currently Amended) A Set or kit, comprising ~~(kit) consisting~~

~~of~~ separate packs of

a) ~~an effective amount of~~ a compound according to Claim 1 or a pharmaceutically acceptable salt thereof ~~and/or physiologically acceptable derivatives, solvates and stereo-isomers thereof, including mixtures thereof in all ratios~~, and

b) an additional pharmaceutically active ingredient ~~an effective amount of a further medicament active ingredient~~.

15. (Cancelled)

16. (Withdrawn and Currently Amended) A method for inhibiting a tyrosine kinase or a Raf kinase, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 ~~Compounds according to Claim 1 and physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, as inhibitors of tyrosine kinases and/or of Raf kinases~~.

17. (Cancelled)

18. (Withdrawn and Currently Amended) A method for treating or preventing a disease that is caused, mediated or propagated by a tyrosine kinase or a Raf kinase or by a tyrosine kinase-mediated transduction or by a Raf kinase-mediated transduction, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases that are caused, mediated and/or propagated by kinases and/or by kinase mediated signal transduction~~.

19. (Cancelled)

20. (Withdrawn and Currently Amended) A method according to claim 18, wherein the tyrosine kinase is ~~Use according to Claim 19, where the tyrosine kinases are~~ TIE-2 or VEGFR.

21. (Cancelled)

22. (Withdrawn and Currently Amended) A method according to claim 18, wherein the Raf kinase is ~~Use according to Claim 21, where the Raf kinases are~~ A-Raf, B-Raf or Raf-1.

23. (Withdrawn and Currently Amended) A method for treating or preventing a solid tumor, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of solid tumours~~.

24. (Withdrawn and Currently Amended) A method ~~Use~~ according to Claim 23, where the solid tumor ~~tumour~~ is selected from the group consisting of brain tumour, tumour of the urogenital tract, tumour of the lymphatic system, stomach tumour, laryngeal tumour and lung tumour.

25. (Withdrawn and Currently Amended) A method ~~Use~~ according to Claim 23, where the solid tumor ~~tumour~~ is selected from the group consisting of monocytic leukaemia, lung adenocarcinoma, small cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.

26. (Withdrawn and Currently Amended) A method for treating or preventing a disease that is ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases that are~~ caused, mediated and/or propagated by angiogenesis, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

27. (Withdrawn and Currently Amended) A method for treating or preventing ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases selected from the group~~

~~consisting of~~ retinal vascularisation, diabetic retinopathy, age-induced macular degeneration or an ~~and/or~~ inflammatory ~~diseases~~ disease, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

28. (Withdrawn and Currently Amended) A method for treating or preventing ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of bone pathologies selected from the group consisting of~~ osteosarcoma, osteoarthritis or ~~and~~ rickets, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

29. (Withdrawn and Currently Amended) A method for treating or preventing ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases selected from the group consisting of~~ psoriasis, rheumatoid arthritis, contact dermatitis, delayed hypersensitivity reaction, inflammation, endometriosis, scarring, benign prostatic hyperplasia, an immunological ~~diseases~~ disease, an autoimmune ~~diseases and~~ disease or an immunodeficiency ~~diseases~~ disease, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

30. (Withdrawn and Currently Amended) A method for treating or preventing ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases selected from the group consisting of~~ brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia or ~~and~~ acute leukaemia, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

31. (Withdrawn and Currently Amended) A pharmaceutical composition according to claim 13, wherein the additional pharmaceutically active ingredient is selected from the

group consisting of ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment and/or prophylaxis of diseases, where a therapeutically effective amount of a compound according to Claim 1 is administered in combination with a compound from the group~~ 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitors, 7) HMG-CoA reductase inhibitors, 8) HIV protease inhibitors 9) reverse transcriptase inhibitors, 10) growth factor receptor inhibitors and 11) angiogenesis inhibitors.

32. (Withdrawn and Currently Amended) A method for treating or preventing a disease that is caused, mediated or propagated by a tyrosine kinase or a Raf kinase or by a tyrosine kinase-mediated transduction or by a Raf kinase-mediated transduction, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 in combination with radiotherapy and a compound selected from the group consisting of ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment and/or prophylaxis of diseases, where a therapeutically effective amount of a compound according to Claim 1 is administered in combination with radiotherapy and a compound from the group~~ 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitors, 7) HMG-CoA reductase inhibitors, 8) HIV protease inhibitors, 9) reverse transcriptase inhibitors, 10) growth factor receptor inhibitors and 11) angiogenesis inhibitors.

33. (New) A compound of formula I



I

in which

$Ar^1$, $Ar^2$, $Ar^3$ each, independently of one another, denote an aromatic radical or Het, each of which is unsubstituted or mono-, di- or polysubstituted by $R^1$,

Het denotes a mono- or bicyclic aromatic heterocycle having 1, 2, 3 or 4 N, O and/or S atoms,

$R^I$ in each case, independently, denotes H, A, aryl, $OR^4$, $SR^4$, Oaryl, Saryl, $N(R^4)_2$, NHaryl, Hal, $NO_2$, CN, $(CH_2)_mCOOR^4$, $(CH_2)_mCOOaryl$, $(CH_2)_mCON(R^4)_2$, $(CH_2)_mCONHaryl$, $COR^4$, COaryl, $S(O)_mA$, $S(O)_maryl$, NHCOA, NHCOaryl, $NHSO_2A$, $NHSO_2aryl$ or $SO_2N(R^4)_2$, $O(CH_2)_n N(R^4)_2$, $O(CH_2)_nNHR_3$, $O(CH_2)_nNH_2$, $O(CH_2)_n$-morpholine, $O(CH_2)_n$-piperazine, $O(CH_2)_n$-pyrrolidine, $O(CH_2)_n$-piperidine, O-piperidine, $O(CH_2)_n$-oxopiperazine, $O(CH_2)_n$-oxomorpholine, $O(CH_2)_n$-oxopyrrolidine, $O(CH_2)_nC(CH_3)_2$-$(CH_2)_nN(R^4)_2$, $N(CH_2)_nC(CH_3)_2(CH_2)_nN(R^4)_2$, $O(CH_2)_nN(R^4)SO_mA$, $O(CH_2)_nN(R^4)SO_mN(R^4)A$, $O(CH_2)_nN(R^4)SO_maryl$, $(CH_2)_nN(R^4)SO_mA$, $(CH_2)_nN(R^4)SO_mN(R^4)A$, $(CH_2)_nN(R^4)SO_maryl$, $O(CH_2)_nSO_mA$, $O(CH_2)_nSO_mN(R^4)A$, $O(CH_2)_nSO_maryl$, $(CH_2)_nSO_mA$, $(CH_2)_nSO_mN(R^4)A$ or ~~and/or~~ $(CH_2)_nSO_maryl$,

Y denotes O, S, C-$NO_2$, $C(CN)_2$ or N-$R^3$,

Z denotes $G^1{}_n$, $G^1{}_nEG^2{}_m$, $EG^1{}_nG^2{}_m$ or $G^1{}_nG^2{}_mE$,

$R^2$, $R^3$, $R^4$ each, independently of one another, denote H, A or -alkylene-aryl,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two $CH_2$ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by Hal,

aryl denotes phenyl which is unsubstituted or mono-, di- or polysubstituted by A, phenyl, OA, SA, Ophenyl, $NH_2$, $NA_2$, Hal, $NO_2$, CN, $(CH_2)_mCOOR^4$, $(CH_2)_mCON(R^4)_2$, $COR^4$, COaryl, $S(O)_mA$, NHCOA or NHSO2A,

E denotes O, $SO_m$, $NR^1$, CO, C=N or alkene,

$G^1$, $G^2$ each, independently of one another, denote $CR^1R^1$ or E,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2, 3, 4 or 5, and

m denotes 0, 1 or 2,

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

34. (New) A compound according to claim 33, wherein the solvate is a mono- or dihydrate of a compound of formula I or an addition compound of a compound of formula I with methanol or ethanol.

35. (New) A compound according to claim 33, wherein the solvate is a hydrate or

an alcoholate of a compound of formula I.

36. (New) A compound according to claim 33, wherein the prodrug is a compound of formula I which has been modified with an alkyl or acyl group, or with a sugar or oligopeptide.